Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis.

Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, Mukaida N.

Cancer Sci. 2007 Mar;98(3):321-8.

3.

Essential contribution of Ets-1 to constitutive Pim-3 expression in human pancreatic cancer cells.

Li YY, Wu Y, Tsuneyama K, Baba T, Mukaida N.

Cancer Sci. 2009 Mar;100(3):396-404. doi: 10.1111/j.1349-7006.2008.01059.x.

4.

Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site.

Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ.

FEBS Lett. 2004 Jul 30;571(1-3):43-9.

5.

Identification of stemonamide synthetic intermediates as a novel potent anticancer drug with an apoptosis-inducing ability.

Li YY, Wang YY, Taniguchi T, Kawakami T, Baba T, Ishibashi H, Mukaida N.

Int J Cancer. 2010 Jul 15;127(2):474-84. doi: 10.1002/ijc.25048.

6.

The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death.

Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M.

J Biol Chem. 2003 Nov 14;278(46):45358-67.

7.

T-18, a stemonamide synthetic intermediate inhibits Pim kinase activity and induces cell apoptosis, acting as a potent anticancer drug.

Wang Z, Li XM, Shang K, Zhang P, Wang CF, Xin YH, Zhou L, Li YY.

Oncol Rep. 2013 Mar;29(3):1245-51. doi: 10.3892/or.2013.2233.

PMID:
23314349
8.

Serine/threonine kinase Pim-2 promotes liver tumorigenesis induction through mediating survival and preventing apoptosis of liver cell.

Gong J, Wang J, Ren K, Liu C, Li B, Shi Y.

J Surg Res. 2009 May 1;153(1):17-22. doi: 10.1016/j.jss.2008.03.033.

PMID:
18675992
9.

Roles of Pim-3, a novel survival kinase, in tumorigenesis.

Mukaida N, Wang YY, Li YY.

Cancer Sci. 2011 Aug;102(8):1437-42. doi: 10.1111/j.1349-7006.2011.01966.x. Review.

10.

Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel.

Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, Tasaka K, Murata Y.

J Biol Chem. 2002 Sep 6;277(36):33490-500.

11.

Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression.

Zheng HC, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, Fujii C, Nomoto K, Mukaida N, Takano Y.

J Cancer Res Clin Oncol. 2008 Apr;134(4):481-8.

PMID:
17876606
12.

A novel regulatory mechanism of Pim-3 kinase stability and its involvement in pancreatic cancer progression.

Zhang F, Liu B, Wang Z, Yu XJ, Ni QX, Yang WT, Mukaida N, Li YY.

Mol Cancer Res. 2013 Dec;11(12):1508-20. doi: 10.1158/1541-7786.MCR-13-0389.

13.

[Effect of ginsenoside Rg3 on Pim-3 and Bad proteins in human pancreatic cancer cell line PANC-1].

Jian J, Hu ZF, Huang Y.

Ai Zheng. 2009 May;28(5):461-5. Chinese.

PMID:
19624871
14.

Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL.

Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ, Arthur JS.

BMC Cell Biol. 2006 Jan 10;7:1.

15.

Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.

Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T, Murata Y.

Cancer Res. 2000 Nov 1;60(21):5988-94.

17.

Constitutively activated FLT3 phosphorylates BAD partially through pim-1.

Kim KT, Levis M, Small D.

Br J Haematol. 2006 Sep;134(5):500-9.

PMID:
16869825
18.

Pim-2 activates API-5 to inhibit the apoptosis of hepatocellular carcinoma cells through NF-kappaB pathway.

Ren K, Zhang W, Shi Y, Gong J.

Pathol Oncol Res. 2010 Jun;16(2):229-37. doi: 10.1007/s12253-009-9215-4.

PMID:
19821157
19.

Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.

Xu D, Cobb MG, Gavilano L, Witherspoon SM, Williams D, White CD, Taverna P, Bednarski BK, Kim HJ, Baldwin AS, Baines AT.

Cancer Biol Ther. 2013 Jun;14(6):492-501. doi: 10.4161/cbt.24343.

20.

Identification of a phenanthrene derivative as a potent anticancer drug with Pim kinase inhibitory activity.

Wang YY, Taniguchi T, Baba T, Li YY, Ishibashi H, Mukaida N.

Cancer Sci. 2012 Jan;103(1):107-15. doi: 10.1111/j.1349-7006.2011.02117.x.

Items per page

Supplemental Content

Support Center